tldrdailynews.com logo

AstraZeneca's Tagrisso Shows Promise in Slowing Lung Cancer Progression

1 min read
Source: STAT
AstraZeneca's Tagrisso Shows Promise in Slowing Lung Cancer Progression
Photo: STAT
TL;DR

AstraZeneca's drug Tagrisso significantly reduces the progression of stage 3 lung cancer by 84% in patients with a specific genetic mutation, potentially changing treatment practices according to experts at the American Society of Clinical Oncology.

Topics:businesshealth#astrazeneca#genetic-mutation#health#lung-cancer#stage-3#tagrisso
Share this article
  1. ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers  STAT
  2. AstraZeneca's Lung, Breast Cancer Drugs Markedly Slow Disease  Bloomberg
  3. Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable EGFR-Mutated NSCLC  OncLive
  4. At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer  MedCity News
  5. LAURA Shows Osimertinib Effective in Treating EGFR+ NSCLC After Chemo/Radiation  Targeted Oncology

Want the full story? Read the original reporting

Read on STAT